Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Discov ; 12(12): 2739-2746, 2022 12 02.
Article in English | MEDLINE | ID: mdl-36458428

ABSTRACT

In 2022, cancer drug development continued to progress rapidly despite the lingering COVID-19 pandemic. Highlights of U.S. drug approvals for oncology indications this year include ongoing development in rare diseases and molecular subgroups, improved dosage optimization, and updated data for drugs granted accelerated approval, with confirmatory studies demonstrating verification of clinical benefit in some instances, as well as indication withdrawal when clinical benefit was not verified.


Subject(s)
COVID-19 Drug Treatment , Pandemics , Humans , Medical Oncology , Drug Development , Drug Approval
SELECTION OF CITATIONS
SEARCH DETAIL
...